.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Fuji
Deloitte
Fish and Richardson
Queensland Health
Farmers Insurance
Express Scripts
Cerilliant
Chinese Patent Office

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,309,707

« Back to Dashboard

Which drugs does patent 7,309,707 protect, and when does it expire?


Patent 7,309,707 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in thirty-six countries.

Summary for Patent: 7,309,707

Title:Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Abstract:The invention relates to a crystalline micronisate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl- )oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Inventor(s): Bender; Helmut (Wiesbaden, DE), Graebner; Hagen (Ingelheim, DE), Schindler; Konrad (Ingelheim, DE), Trunk; Michael (Ingelheim, DE), Walz; Michael (Bingen, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/385,175
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimSPIRIVAtiotropium bromidePOWDER;INHALATION021395-001Jan 30, 2004RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,309,707

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 12 264Mar 20, 2002

Non-Orange Book Patents for Patent: 7,309,707

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,642,268Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,309,707

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland220730► Subscribe
Poland371799► Subscribe
Peru08382003► Subscribe
New Zealand535808► Subscribe
Norway20044003► Subscribe
Malaysia139720► Subscribe
MexicoPA04009056► Subscribe
MontenegroP46708► Subscribe
Lithuania1785422► Subscribe
South Korea101094091► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Department of Justice
Queensland Health
Farmers Insurance
Federal Trade Commission
UBS
Harvard Business School
Cantor Fitzgerald
Argus Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot